Identification of G Protein-Biased Agonists That Fail to Recruit β-Arrestin or Promote Internalization of the D1 Dopamine Receptor

ACS Chemical Neuroscience

Volumn 6, Issue 4, 2015, Pages 681-692

  Conroy, Jennie L ^a   Free, R Benjamin ^a   Sibley, David R ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

biased agonism; D1 receptor; Dopamine; functional selectivity; G protein; arrestin, benzazepine

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 PHENYL 1H 3 BENZAZEPINE; 3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; 3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; APOMORPHINE; BENZAZEPINE DERIVATIVE; BETA ARRESTIN; CYCLIC AMP; DIHYDREXIDINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 5 RECEPTOR; FENOLDOPAM; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; SKF 82957; SKF 83822; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR STIMULATING AGENT; RETINA S ANTIGEN;

ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG SELECTIVITY; EC50; ENDOCYTOSIS; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTERNALIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; METABOLISM; RADIOASSAY; TUMOR CELL LINE;

ANIMALS; ARRESTINS; BENZAZEPINES; CELL LINE, TUMOR; CELL MEMBRANE; CHO CELLS; CRICETULUS; CYCLIC AMP; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D5; TRANSFECTION;

EID: 84927917283     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00020     Document Type: Article

References (66)

1. Rankin, M. L., Hazelwood, L. A., Free, R. B., Namkung, Y., Rex, E. B., Roof, R. A., and Sibley, D. R. (2009) Molecular pharmacology of the dopamine receptors. In Dopamine Handbook (Iversen, L. L., Iversen, S. D., Dunnett, S. B., and Bjorklund, A., Eds.) pp 63 - 87, Oxford University Press, New York.
2. Kapur, S. and Mamo, D. (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27, 1081 - 1090
3. Sibley, D. R. and Monsma, F. J., Jr. (1992) Molecular biology of dopamine receptors Trends Pharmacol. Sci. 13, 61 - 69
4. Beaulieu, J. M. and Gainetdinov, R. R. (2011) The physiology, signaling, and pharmacology of dopamine receptors Pharmacol. Rev. 63, 182 - 217
5. Swinney, D. C. (2006) Successful drug discovery Curr. Top. Med. Chem. 6, 403 - 404
6. Walters, R. W., Shukla, A. K., Kovacs, J. J., Violin, J. D., DeWire, S. M., Lam, C. M., Chen, J. R., Muehlbauer, M. J., Whalen, E. J., and Lefkowitz, R. J. (2009) β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice J. Clin. Invest. 119, 1312 - 1321
7. Kobilka, B. K. and Deupi, X. (2007) Conformational complexity of G-protein-coupled receptors Trends Pharmacol. Sci. 28, 397 - 406
8. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2007) Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320, 1 - 13
9. Wess, J., Han, S. J., Kim, S. K., Jacobson, K. A., and Li, J. H. (2008) Conformational changes involved in G-protein-coupled-receptor activation Trends Pharmacol. Sci. 29, 616 - 625
10. Whalen, E. J., Rajagopal, S., and Lefkowitz, R. J. (2011) Therapeutic potential of β-arrestin- and G protein-biased agonists Trends Mol. Med. 17, 126 - 139
11. Kenakin, T. (2007) Collateral efficacy in drug discovery: Taking advantage of the good (allosteric) nature of 7TM receptors Trends Pharmacol. Sci. 28, 407 - 415
12. Kenakin, T. (2007) Functional selectivity through protean and biased agonism: Who steers the ship? Mol. Pharmacol. 72, 1393 - 1401
13. Kenakin, T. P. (2008) Pharmacological onomastics: What's in a name? Br. J. Pharmacol. 153, 432 - 438
14. Mailman, R. B. (2007) GPCR functional selectivity has therapeutic impact Trends Pharmacol. Sci. 28, 390 - 396
15. Abdul-Ridha, A., Lopez, L., Keov, P., Thal, D. M., Mistry, S. N., Sexton, P. M., Lane, J. R., Canals, M., and Christopoulos, A. (2014) Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor J. Biol. Chem. 289, 6067 - 6079
16. Dror, R. O., Green, H. F., Valant, C., Borhani, D. W., Valcourt, J. R., Pan, A. C., Arlow, D. H., Canals, M., Lane, J. R., Rahmani, R., Baell, J. B., Sexton, P. M., Christopoulos, A., and Shaw, D. E. (2013) Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs Nature 503, 295 - 299
17. Kruse, A. C., Ring, A. M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hubner, H., Pardon, E., Valant, C., Sexton, P. M., Christopoulos, A., Felder, C. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. C., Wess, J., and Kobilka, B. K. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 504, 101 - 106
18. Liu, J. J., Horst, R., Katritch, V., Stevens, R. C., and Wuthrich, K. (2012) Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR Science 335, 1106 - 1110
19. Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L., and Stevens, R. C. (2013) Structural features for functional selectivity at serotonin receptors Science 340, 615 - 619
20. Kilts, J. D., Connery, H. S., Arrington, E. G., Lewis, M. M., Lawler, C. P., Oxford, G. S., O'Malley, K. L., Todd, R. D., Blake, B. L., Nichols, D. E., and Mailman, R. B. (2002) Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs J. Pharmacol. Exp. Ther. 301, 1179 - 1189
21. Mottola, D. M., Kilts, J. D., Lewis, M. M., Connery, H. S., Walker, Q. D., Jones, S. R., Booth, R. G., Hyslop, D. K., Piercey, M., Wightman, R. M., Lawler, C. P., Nichols, D. E., and Mailman, R. B. (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase J. Pharmacol. Exp. Ther. 301, 1166 - 1178
22. Gay, E. A., Urban, J. D., Nichols, D. E., Oxford, G. S., and Mailman, R. B. (2004) Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: Evidence for induction of ligand-specific receptor states Mol. Pharmacol. 66, 97 - 105
23. Lane, J. R., Powney, B., Wise, A., Rees, S., and Milligan, G. (2007) Protean agonism at the dopamine D2 receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1,Gi2, and Gi3 Mol. Pharmacol. 71, 1349 - 1359
24. Lane, J. R., Powney, B., Wise, A., Rees, S., and Milligan, G. (2008) G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors J. Pharmacol. Exp. Ther. 325, 319 - 330
25. Beaulieu, J. M., Gainetdinov, R. R., and Caron, M. G. (2007) The Akt-GSK-3 signaling cascade in the actions of dopamine Trends Pharmacol. Sci. 28, 166 - 172
26. Beaulieu, J. M., Gainetdinov, R. R., and Caron, M. G. (2009) Akt/GSK3 signaling in the action of psychotropic drugs Annu. Rev. Pharmacol. Toxicol. 49, 327 - 347
27. Free, R. B., Chun, L. S., Moritz, A. E., Miller, B. N., Doyle, T. B., Conroy, J. L., Padron, A., Meade, J. A., Xiao, J., Hu, X., Dulcey, A. E., Han, Y., Duan, L., Titus, S., Bryant-Genevier, M., Barnaeva, E., Ferrer, M., Javitch, J. A., Beuming, T., Shi, L., Southall, N. T., Marugan, J. J., and Sibley, D. R. (2014) Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor Mol. Pharmacol. 86, 96 - 105
28. Allen, J. A., Yost, J. M., Setola, V., Chen, X., Sassano, M. F., Chen, M., Peterson, S., Yadav, P. N., Huang, X. P., Feng, B., Jensen, N. H., Che, X., Bai, X., Frye, S. V., Wetsel, W. C., Caron, M. G., Javitch, J. A., Roth, B. L., and Jin, J. (2011) Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy Proc. Natl. Acad. Sci. U.S.A. 108, 18488 - 18493
29. Chen, X., Sassano, M. F., Zheng, L., Setola, V., Chen, M., Bai, X., Frye, S. V., Wetsel, W. C., Roth, B. L., and Jin, J. (2012) Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D(2) receptor agonists J. Med. Chem. 55, 7141 - 7153
30. Undie, A. S. and Friedman, E. (1990) Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain J. Pharmacol. Exp. Ther. 253, 987 - 992
31. Undie, A. S. and Friedman, E. (1992) Selective dopaminergic mechanism of dopamine and SKF38393 stimulation of inositol phosphate formation in rat brain Eur. J. Pharmacol. 226, 297 - 302
32. Downes, R. P. and Waddington, J. L. (1993) Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine 'D1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase Eur. J. Pharmacol. 234, 135 - 136
33. Deveney, A. M. and Waddington, J. L. (1995) Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase Br. J. Pharmacol. 116, 2120 - 2126
34. Panchalingam, S. and Undie, A. S. (2001) SKF83959 exhibits biochemical agonism by stimulating [35S]GTPγS binding and phosphoinositide hydrolysis in rat and monkey brain Neuropharmacology 40, 826 - 837
35. Jin, L. Q., Goswami, S., Cai, G., Zhen, X., and Friedman, E. (2003) SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain J. Neurochem. 85, 378 - 386
36. Lee, S. P., So, C. H., Rashid, A. J., Varghese, G., Cheng, R., Lanca, A. J., O'Dowd, B. F., and George, S. R. (2004) Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal J. Biol. Chem. 279, 35671 - 35678
37. Rashid, A. J., So, C. H., Kong, M. M., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B. F., and George, S. R. (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum Proc. Natl. Acad. Sci. U.S.A. 104, 654 - 659
38. Perreault, M. L., Shen, M. Y., Fan, T., and George, S. R. (2014) Regulation of c-fos expression by the dopamine D1-D2 receptor heteromer Neuroscience 285C, 194 - 203
39. Chun, L. S., Free, R. B., Doyle, T. B., Huang, X. P., Rankin, M. L., and Sibley, D. R. (2013) D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms Mol. Pharmacol. 84, 190 - 200
40. Lee, S. M., Kant, A., Blake, D., Murthy, V., Boyd, K., Wyrick, S. J., and Mailman, R. B. (2014) SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C Neuropharmacology 86, 145 - 154
41. Lee, S. M., Yang, Y., and Mailman, R. B. (2014) Dopamine D1 receptor signaling: Does GαQ-phospholipase C actually play a role? J. Pharmacol. Exp. Ther. 351, 9 - 17
42. Andringa, G., Stoof, J. C., and Cools, A. R. (1999) Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: Stable therapeutic effects and wearing-off dyskinesia Psychopharmacology 146, 328 - 334
43. Fang, X., Guo, L., Jia, J., Jin, G. Z., Zhao, B., Zheng, Y. Y., Li, J. Q., Zhang, A., and Zhen, X. C. (2013) SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity Acta Pharmacol. Sin. 34, 1149 - 1155
44. Guo, L., Zhao, J., Jin, G., Zhao, B., Wang, G., Zhang, A., and Zhen, X. (2013) SKF83959 is a potent allosteric modulator of sigma-1 receptor Mol. Pharmacol. 83, 577 - 586
45. Urs, N. M., Daigle, T. L., and Caron, M. G. (2011) A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice Neuropsychopharmacology 36, 551 - 558
46. Mailman, R. B. and Nichols, D. E. (1998) Dopamine D1 receptor agonists as antiparkinson drugs Trends Pharmacol. Sci. 19, 255 - 256
47. Arnsten, A. F., Cai, J. X., Murphy, B. L., and Goldman-Rakic, P. S. (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys Psychopharmacology 116, 143 - 151
48. Goldman-Rakic, P. S. (1994) Working memory dysfunction in schizophrenia J. Neuropsychiatry Clin. Neurosci. 6, 348 - 357
49. Nichols, D. E. (2009) Dopamine Receptor Subtype-Selective Drugs: D1-Like Receptors. In The Dopamine Receptors (Neve, K. A., Ed.) 2nd ed., pp 75 - 100, Humana Press, Totowa, NJ.
50. Weed, M. R., Vanover, K. E., and Woolverton, W. L. (1993) Reinforcing effect of the D1 dopamine agonist SKF 81297 in rhesus monkeys Psychopharmacology 113, 51 - 52
51. Undie, A. S., Weinstock, J., Sarau, H. M., and Friedman, E. (1994) Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain J. Neurochem. 62, 2045 - 2048
52. Peacock, L. and Gerlach, J. (2001) Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: Evidence of uncharted dopamine D1 receptor actions Biol. Psychiatry 50, 501 - 509
53. Chausmer, A. L. and Katz, J. L. (2002) Comparison of interactions of D1-like agonists, SKF 81297, SKF 82958 and A-77636, with cocaine: Locomotor activity and drug discrimination studies in rodents Psychopharmacology 159, 145 - 153
54. Nichols, A. J., Ruffolo, R. R., Jr., and Brooks, D. P. (1990) The pharmacology of fenoldopam Am. J. Hypertens. 3, 116S - 119S
55. Arnt, J., Hyttel, J., and Sanchez, C. (1992) Partial and full dopamine D1 receptor agonists in mice and rats: Relation between behavioural effects and stimulation of adenylate cyclase activity in vitro Eur. J. Pharmacol. 213, 259 - 267
56. Lewis, M. M., Watts, V. J., Lawler, C. P., Nichols, D. E., and Mailman, R. B. (1998) Homologous desensitization of the D1A dopamine receptor: Efficacy in causing desensitization dissociates from both receptor occupancy and functional potency J. Pharmacol. Exp. Ther. 286, 345 - 353
57. Ryman-Rasmussen, J. P., Nichols, D. E., and Mailman, R. B. (2005) Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists Mol. Pharmacol. 68, 1039 - 1048
58. Glick, S. D., Carlson, J. N., Baird, J. L., Maisonneuve, I. M., and Bullock, A. E. (1988) Basal and amphetamine-induced asymmetries in striatal dopamine release and metabolism: Bilateral in vivo microdialysis in normal rats Brain Res. 473, 161 - 164
59. Schulz, D. W., Stanford, E. J., Wyrick, S. W., and Mailman, R. B. (1985) Binding of [3H]SCH23390 in rat brain: Regional distribution and effects of assay conditions and GTP suggest interactions at a D1-like dopamine receptor J. Neurochem. 45, 1601 - 1611
60. Oakley, R. H., Laporte, S. A., Holt, J. A., Caron, M. G., and Barak, L. S. (2000) Differential affinities of visual arrestin, β arrestin1, and β arrestin2 for G protein-coupled receptors delineate two major classes of receptors J. Biol. Chem. 275, 17201 - 17210
61. DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X. T., Pitis, P. M., Gotchev, D., Yuan, C., Koblish, M., Lark, M. W., and Violin, J. D. (2013) A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine J. Pharmacol. Exp. Ther. 344, 708 - 717
62. Fieblinger, T., Sebastianutto, I., Alcacer, C., Bimpisidis, Z., Maslava, N., Sandberg, S., Engblom, D., and Cenci, M. A. (2014) Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5 J. Neurosci. 34, 4728 - 4740
63. Friedman, E., Jin, L. Q., Cai, G. P., Hollon, T. R., Drago, J., Sibley, D. R., and Wang, H. Y. (1997) D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: Evidence from D1A knockout mice Mol. Pharmacol. 51, 6 - 11
64. Frederick, A. L., Yano, H., Trifilieff, P., Vishwasrao, H. D., Biezonski, D., Meszaros, J., Sibley, D. R., Kellendonk, C., Sonntag, K. C., Graham, D. L., Colbran, R. J., Stanwood, G. D., and Javitch, J. A. (2015) Evidence against dopamine D1/D2 receptor heteromers Mol. Psychiatry DOI: 10.1038/mp.2014.16
65. Banala, A. K., Levy, B. A., Khatri, S. S., Furman, C. A., Roof, R. A., Mishra, Y., Griffin, S. A., Sibley, D. R., Luedtke, R. R., and Newman, A. H. (2011) N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: Critical role of the carboxamide linker for D3 receptor selectivity J. Med. Chem. 54, 3581 - 3594
66. Bergman, J., Roof, R. A., Furman, C. A., Conroy, J. L., Mello, N. K., Sibley, D. R., and Skolnick, P. (2013) Modification of cocaine self-administration by buspirone (buspar(R)): Potential involvement of D3 and D4 dopamine receptors Int. J. Neuropsychopharmacol. 16, 445 - 458